Briefs: Sun Pharma and Kimia Biosciences

Sun Pharma's Dadra facility receives OAI status from US FDA

Sun Pharma's Dadra facility receives OAI status from US FDA

The US FDA conducted an inspection at Sun Pharmaceutical Industries Limited's Dadra facility from December 4, 2023 to December 15, 2023. US FDA has subsequently determined that the inspection classification status of this facility as Official Action Indicated (OAI).

Kimia Biosciences receives confirmation for active substances import into EU

Kimia Biosciences Ltd has received the written confirmation for active substances imported into the European Union for medical products for human use, in accordance with Article 46(b)(2)(b) of Directives 2001/83/EC from Government of India, Ministry of Health & Family welfare, Central Drug Standard Control Organization vide Certificate no WC-0474. The confirmation is received for one product Vildagliptin IH.